Humacyte Inc

For the period ended Jun 30, 2024. Filed Aug 13, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 13, 2024

HUMA$0.59+29.6%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands except for share and per share amounts)

	For the Three Months Ended June 30,		For the Six Months Ended June 30,
	2024	2023	2024	2023
Revenue	$—	$—	$—	$—
Operating expenses:
Research and development	23,753	20,540	45,017	37,818
General and administrative	5,746	6,191	11,060	11,425
Total operating expenses	29,499	26,731	56,077	49,243
Loss from operations	(29,499)	(26,731)	(56,077)	(49,243)
Other income (expense), net:
Interest income	1,310	1,479	2,341	2,954
Change in fair value of Contingent Earnout Liability	(25,571)	3,627	(30,164)	(10,564)
Interest expense	(2,515)	(1,710)	(4,331)	(3,409)
Change in fair value of derivative liabilities	(388)	(57)	(328)	(99)
Employee retention credit	—	3,107	—	3,107
Loss on extinguishment of debt	—	(2,421)	—	(2,421)
Total other income (expense), net	(27,164)	4,025	(32,482)	(10,432)
Net loss and comprehensive loss	$(56,663)	$(22,706)	$(88,559)	$(59,675)
Net loss per share attributable to common stockholders, basic and diluted	$(0.48)	$(0.22)	$(0.78)	$(0.58)
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted	119,174,681	103,361,501	113,710,344	103,312,785

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.